← FDA DRUG APPROVALS

FDA ANDA · ANDA065001

CEFUROXIME SODIUM

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA065001
TYPE
ANDA
ORIGINAL APPROVAL
2001-05-30
LATEST ACTION
2011-11-10
ROUTE
INJECTION, INTRAMUSCULAR, INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFUROXIME SODIUMDiscontinued
CEFUROXIME SODIUM EQ 1.5GM BASE/VIAL · INJECTABLE · INJECTION
CEFUROXIME SODIUMDiscontinued
CEFUROXIME SODIUM EQ 750MG BASE/VIAL · INJECTABLE · INTRAMUSCULAR, INTRAVENOUS

Approval history

2011-11-10Labeling · Supplement 6AP
2004-02-20Labeling · Supplement 4AP
2002-11-12Labeling · Supplement 2AP
2002-03-28Manufacturing (CMC) · Supplement 1AP
2001-05-30OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →